

Published in final edited form as:

Free Radic Biol Med. 2009 August 15; 47(4): 344–356. doi:10.1016/j.freeradbiomed.2009.05.018.

Regulation of Superoxide Dismutase Genes: Implications in

Diseases

Lu Miao and Daret K. St. Clair*

Graduate Center for Toxicology, University of Kentucky, Lexington, KY 40536, USA

Abstract

Numerous short-lived and highly reactive oxygen species (ROS) such as $O_2^{\cdot-}$ (superoxide), $\cdot OH$ (hydroxyl radical), and H_2O_2 (hydrogen peroxide) are continuously generated *in vivo*. Depending upon concentration, location and intracellular conditions, ROS can cause toxicity or act as signaling molecules. The cellular levels of ROS are controlled by antioxidant enzymes and small molecule antioxidants. As major antioxidant enzymes, superoxide dismutases (SODs), including copper-zinc superoxide dismutase (Cu/ZnSOD), manganese superoxide dismutase (MnSOD) and extracellular superoxide dismutase (ECSOD), play a crucial role in scavenging $O_2^{\cdot-}$. This review focuses on the regulation of the genes (*sods*) coding for these enzymes with an emphasis on human genes. Current knowledge about *sods* structure and their regulation is summarized and depicted as diagrams.

Studies to date on genes coding for Cu/ZnSOD (*sod1*) are mostly focused on alteration in the coding region and their associations with Amyotrophic Lateral Sclerosis (ALS). Evaluation of nucleotide sequences reveals that regulatory elements of the *sod2* gene reside in both the non-coding and coding regions. Changes associated with *sod2* lead to alteration in expression levels as well as protein function. We also discuss the structural basis for the changes in SOD expression associated with pathological conditions and where more work is needed to establish the relationship between SODs and diseases.

Keywords

Superoxide Dismutase; Gene Regulation; Oxidative Stress-related Disease

Introduction

Oxidative stress caused by the imbalance between reactive oxygen species (ROS) or reactive nitrogen species (RNS) and biological antioxidant system can lead to modification of macromolecules such as DNA, lipid and protein [1-3]. Because the redox status (oxidizing/reducing conditions) of cells is involved in regulating various transcription factors/activators (e.g., AP-1, NF- κ B and p53), thereby influencing cellular target gene expression and modulating cellular signaling pathways, appropriate ROS and RNS levels are necessary for normal physiological function of the living organisms [4]. However, excessive redox active species may cause DNA damage, repress the activity of cellular enzymes and induce cell death through activation of kinases and caspase cascades [5-8].

*Author to whom correspondence should be addressed: Daret K. St.Clair, Ph.D., Graduate Center for Toxicology, University of Kentucky, 1095 VA Drive, HSRB 454, Lexington, KY 40536-0298, Phone: 1-(859) 257-3956, FAX: 1-(859) 323-1059, Email: dstcl00@uky.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

To ameliorate and cope with injury from oxidative damage and maintain redox homeostasis, aerobic organisms have developed efficient defense systems of enzymatic and non-enzymatic antioxidants. The superoxide dismutase family is specialized in eliminating superoxide anion radicals derived from extracellular stimulants, including ionizing radiation and oxidative insults, together with those primarily produced within the mitochondrial matrix as byproducts of oxygen metabolism through the electron transport chain [9]. Three distinct isoforms of SOD have been identified and characterized in mammals: copper-zinc superoxide dismutase (Cu/ZnSOD, encoded by the *sod1* gene), manganese superoxide dismutase (MnSOD, encoded by the *sod2* gene) and extracellular superoxide dismutase (ECSOD, encoded by the *sod3* gene). These forms of SODs elicit similar functions, but characteristics of their protein structures, chromosome localizations, metal cofactor requirements, gene distributions and cellular compartmentalization are distinctly different from one another (reviewed in [10]). Genetic comparisons indicate that similarities exist in *sod1* and *sod3* genes in certain levels of the amino acid homology while *sod2* does not share substantial amino acid homology with either *sod1* or *sod3* [10]. The unique features of each SOD in terms of molecular weight, cellular localization, assembly of subunits, metal cofactor requirements and ion-delivery related proteins are summarized in Table 1.

Regulation of *sod* genes plays a pivotal role in balancing the concentration of ROS. The compartmentalization and control of SODs at both expression and activity levels contribute to the level of SOD and consequent localized ROS level [21,22]. This review focuses on recent progress made on *sod* gene regulation. Given that SODs have important functions beyond the essential role of *sod2* for survival in the aerobic environment, their association with diseases such as neurodegenerative diseases, pulmonary and cardiovascular dysfunction, cancer development and progression [19,23-27] is also discussed. Knowledge of how the expression of *sod* genes is modulated would provide insight into the understanding of human diseases and facilitate the development of therapeutic interventions.

Genetic structures and organization of the *sod* genes

sod1

The chromosomal localization and characteristics of the *sod1* gene have been identified in rodents [28], bovines [29] and humans [30]. The human *sod1* gene is localized on chromosome 21q22 [30]. The latest information on *sod* genes sequences is generated from initial sequencing data and comparative analysis of whole genomic studies among different species. Sequence comparison has revealed that the *sod1* gene consists of five exons interrupted by 4 introns, which is significantly similar in all these species, in terms of the size of exons particularly the coding regions (Fig. 1). The variation of intron size found in different studies may be associated with gene polymorphisms in different human tissues and cell lines. Because not all information on a specific gene, e.g., the transcription initiation site, is available from online databases, original sources on characterization and organization of *sod* genes are used as references to evaluate the gene regulation studies. The *sod1* promoter has a high GC-rich region, as well as TATA box and CCAAT box. Several putative transcription factors binding sites in the promoter region that have been verified by subsequent functional studies are summarized in Figure 1.

sod2

Among the three SOD isoforms, *sod2* has a unique genetic organization and little similarity with *sod1* and *sod3*. In addition to the human gene, the complete genomic sequence of the *sod2* gene has been isolated and characterized for other species such as mouse [31,32], rat [33] and bovine [34]. The primary structure of *sod2* genes is highly conserved and shares more than 90% sequence homology in the coding region [35], which is summarized in Figure 2. The human *sod2* is located on chromosome 6q25.3. Two forms of human *sod2* transcripts exist,

but no significant difference exists between the lengths of translation residues. Based on molecular structure and organization of the human *sod2* gene, five exons interrupted by 4 introns have been identified. The basal promoter of the *sod2* gene lacks TATA and CAAT boxes but contains GC rich motifs and numerous Sp1 as well as several AP-2 consensus sequences in its proximal promoter region [36].

sod3

The human *sod3* gene is localized on chromosome 4. The *sod3* gene consists of 3 exons and 2 introns. An uninterrupted coding region is present within exon 3, which is homologous to the *sod1* gene [37,38]. However, an updated database shows only two exons and excludes the 5bp exon 1 containing the transcription start site. Thus, the underlying functions of this short exon and the precise location of the first exon remain to be evaluated. Two CAAT box elements but not the classical TATA box have been found in the *sod3* promoter region [38]. Information on the *sod3* cDNA sequence for rat and mouse is also available [39,40]. The full-length mouse *sod3* cDNA is 82% identical to rat but only 60% identical to human ECSOD [40]. Several transcription factors binding elements are present and they are depicted in Figure 3.

Transcriptional factors involved in the regulation of the *sod* genes

Results of computer analysis have revealed many transcriptional regulatory elements in the proximal promoter regions of the *sod* genes that are binding sites for several common transcription factors. These transcriptional factors, including NF- κ B, AP-1, AP-2 and Sp1, as well as C/EBP, have been shown to play important roles in regulating the constitutive or inductive expression levels of all three SODs.

Nuclear Factor-KappaB (NF- κ B)

The redox-sensitive transcriptional factor NF- κ B acts as a regulator of genes by serving as an “immediate responder” to harmful cellular stimuli. NF- κ B responsive elements have been found in both promoter and intronic regions of all three *sod* genes [41-43]. Because the *sod1* gene is often constitutively expressed and not as easily inducible as other superoxide dismutases, it is considered a “housekeeper gene” and is sometimes used as an internal control to compare variations in MnSOD expression level or activity [44]. Though the NF- κ B site in the *sod1* promoter is not very responsive to external stimuli, the PI3K/Akt pathway can activate NF- κ B and upregulate Cu/ZnSOD expression [45]. The presence of the superoxide permeability pathway in endosomal membranes suggests that Cu/ZnSOD mediates O₂⁻ dismutation at the endosomal surface and may produce the localized H₂O₂ required for redox activation of NF- κ B [46]. Interestingly, activation of NF- κ B is absent not only in *sod1* overexpressing cells but also in Cu/ZnSOD deficient mice [47,48].

The induction of *sod2* in response to oxidative stress has been well established in organisms, tissues and cells growing under various stress conditions. Stimuli such as ionizing radiation [49,50], 12-O-tetradecanoylphorbol-13-acetate (TPA) [51], interferon-gamma (IFN- γ) [52] and proinflammatory cytokines, such as tumor necrosis factor α (TNF α) [53,54], interleukin-1beta (IL-1 β) [55], interleukin-4 (IL-4) and interleukin-6 (IL-6), can rapidly modulate *sod2* gene transcription [56]. Previous studies from our laboratory and by other investigators have demonstrated that the stimulus-dependent MnSOD mRNA level elevation is controlled at the transcription level [57]. In one of these studies, NF- κ B was identified as the most crucial transcriptional factor regulating MnSOD induction [49]. Interestingly, functional studies have demonstrated that while the NF- κ B site located within the second intron of the *sod2* gene is necessary for cytokine-mediated induction of MnSOD expression [43, 58-60], p50, a member of the NF- κ B family, elicits a negative role in *sod2* expression [61].

The regulatory effects of different stimuli such as cytokines, vasoactive factors, nitric oxide, cyclic nucleotides and angiotensin II on *sod3* have been reviewed previously [20,62]. A putative NF- κ B motif in the human *sod3* promoter region has been proposed as the functional transcriptional binding site contributing to induction and coregulation of nitric oxide synthase (iNOS) and ECSOD [38,42,63]. However, the location of this regulatory element has not been functionally identified. An additional NF- κ B site has been identified in the second intron, but its regulatory role in ECSOD expression remains unclear [42].

Specificity Protein 1 (Sp1)

Sp1 is a zinc-finger protein that acts as a transcription factor by binding directly to DNA through three consecutive zinc-finger domains in the C-terminus and enhances gene transcription with one of the two glutamine-rich domains [64-66]. The existence of multiple GC boxes is the identifiable characteristic of the Sp1-dependent promoter. Thus, the GC-rich motif contained within the three *sod* gene promoters suggests a common regulatory role of Sp1 in the expression of SODs [67,68].

Sp1 is a zinc-finger protein that acts as a transcription factor by binding directly to DNA through three consecutive zinc-finger domains in the C-terminus and enhances gene transcription with one of the two glutamine-rich domains [64-66]. The existence of multiple GC boxes is the identifiable characteristic of the Sp1-dependent promoter. Thus, the GC-rich motif contained within the three *sod* gene promoters suggests a common regulatory role of Sp1 in the expression of SODs [67,68].

Sp1 is necessary for both basal transcription and TPA-induced transcription via non-canonical binding sites of the *sod1* proximal promoter region [44,69]. Consistently, *sod1* basal promoter activity has been significantly elevated by ectopically overexpressing Sp1 [70]. Studies have shown that DNA binding and promoter activity can be completely abolished by mutations in the Sp1/Egr-1 site [70]. Thus, Sp1 can directly activate *sod1* by binding to DNA. Sp1 can also interact with other proteins to enhance the expression of *sod1*. For example, the expression of Cu/ZnSOD in both neuronal and non-neuronal cell lines is modulated by Sp1 activity through direct interaction with neuronal nitric oxide synthase (nNOS) in the cytosol as well as in the nucleus [71].

In the 5'-flanking region of *sod2*, transcription factor Sp1 is essential for not only the constitutive but also the inducible expression of MnSOD [67,72]. The importance of the Sp1 binding site on endogenous *sod2* promoter activity has been confirmed by potentially unbiased PIN*POINT (Protein Position Identification with Nuclease Tail) analysis *in vivo* [73]. Multiple Sp1 binding elements are needed to induce *sod2* expression via the proximal promoter and the intronic enhancer element. A unique DNA looping structure in the 5'-flanking region formed by direct interactions between distant and local Sp1 is able to synergistically activate transcription *in vivo* [74]. This unique single-strand structure of the *sod2* promoter creates the required structure for RNA-binding proteins, such as nucleophosmin (NPM). NPM binds to an 11G single-strand loop structure in the *sod2* promoter region and integrates Sp1 and NF- κ B responses. Disruption of this loop structure impairs constitutive and inductive transcriptions [75]. The binding of NPM to this loop structure enables Sp1, NF- κ B and other important transcription factors, such as p53, to interact and exert a positive or negative effect on the expression of *sod2* [76]. This complex relationship between transcription factors may explain the alteration of *sod2* expression as a disease progresses.

It has been demonstrated that binding of Sp1/Sp3 transcription factors to the human *sod3* gene proximal promoter region is essential for trichostatin A (TSA) dependent and basal transcription of *sod3* because deletion of the Sp1 binding site significantly abolishes this activation [77]. This role of Sp1/Sp3 has also been demonstrated in lung fibroblasts [78]. Thus,

it is unclear whether the presence of Sp1 is absolutely essential or other members of the Sp family are able to compensate for Sp1 function for the expression of *sod3*.

Activator Protein 1 (AP-1)

AP-1 is a homo- or hetero-dimeric protein composed of proteins belonging to the c-Fos, c-Jun and Fra families. AP-1 acts as a transcriptional regulator to modulate signal transduction processes involved in cell proliferation and transformation [79]. Studies of the redox regulation of AP-1 oncogenes have been excellently reviewed [4]. The expression of *c-fos* and *c-jun* genes is responsive to a variety of stimuli, including cytokines, growth factors and oxidative stress. However, the increased DNA binding capacity of AP-1 could cause a reduction in Cu/ZnSOD [71]. The activity of AP-1 is also subject to redox regulation. Thus, alteration in *sod* genes expression also modulates AP-1 activity [80,81]. In a skin cancer model, overexpression of the *sod2* gene in transgenic mice results in reduced tumor incidence by suppressing AP-1 activation whereas MnSOD deficiency enhances AP-1 and p53 levels, as well as increases proliferation and apoptosis events [82]. Increased MnSOD in response to oxidative stress during hepatitis C replication is regulated by two distinct signaling pathways involving p38 MAPK and JNK via AP-1 [83]. Therefore, AP-1 could activate the expression of *sod* genes and could be activated by the expression of SODs.

Activating Protein 2 (AP-2)

AP-2 is a family of closely related transcription factors consisting of AP-2alpha, AP-2beta, AP-2gamma, AP-2delta and AP-2epsilon [84]. In addition to directly binding to the *cis*-element in the target gene, AP-2 is able to crosstalk with other transcriptional factors to alter the expression of a specific gene [85]. Ginsenoside Rb₂, purified from the panaxadiol fractions of Panax ginseng extracts, is able to increase *sod1* transcription through the AP-2 site [86]. On the other hand, AP-2 plays a negative role in the constitutively low expression of MnSOD by suppressing Sp1-dependent transcription [67,87,88]. A methylated AP-2 binding site in the *sod2* promoter reduces AP-2 DNA binding and relieves transcriptional repression of MnSOD [89]. Thus, the binding of AP-2 to the *sod2* promoter may have a negative effect on MnSOD expression. Consistent with this possibility, a low Sp1/AP-2 ratio plays a role in dysregulating the promoter activity of the *sod2* gene. Consequently, the loss of AP-2 activity in several types of human cancer may explain a high level of MnSOD in these cancers.

CCAAT-Enhancer-Binding Proteins (C/EBP)

C/EBP proteins consist of six members, C/EBP α to C/EBP ζ , which can interact with the CCAAT box motif present in many gene promoters. The binding of C/EBPs to DNA requires that homo- or hetero- dimerization be formed within the various members of the C/EBP family or with other transcription factors [90]. C/EBP-related factors are necessary for basal *sod1* transcription [69]. Of the known C/EBP family members, C/EBP α and C/EBP β play similar roles in stimulating the human *sod1* gene. C/EBP α also plays a major role in activating the transcription of the rat *sod1* gene [91,92]. The C/EBP binding site located in the *sod2* intronic enhancer region elicits the supportive role of MnSOD induction in response to cytokine stimulation. Various C/EBP isoforms, C/EBP β /LAP*, C/EBP β /LAP, C/EBP β /LIP and C/EBP δ , perform distinct functions in MnSOD transcription [58,93]. A C/EBP β -binding site located between -242 and -178 in the promoter region of the *sod3* gene has been identified by deletion analysis of the *sod3* promoter-luciferase construct. This C/EBP β -binding site is also involved in the induction of ECSOD mRNA and protein levels, as well as confers resistance to insulin [94].

Unique Transcriptional Factors

The five transcriptional factors discussed above share relatively common effects on the regulation of all three superoxide dismutase genes. Because of the structural characteristics and organization of each gene sequence, several transcription factors play a unique regulatory role in the expression of superoxide dismutase isoforms. For example, arachidonic acid induces the rat *sod1* gene through the peroxisome proliferator-responsive element (PPRE) in the 5'-flanking sequence [95]. The transcription factors Elk1 and YY1, which bind to the positive and negative regulatory elements in the upstream region of the rat *sod1* gene, respectively, coordinate the expression of rat *sod1* [96]. The anticancer drug mitomycin C inhibits *sod1* gene transcription through p53-mediated transcriptional repression [97]. In addition, xenobiotics such as TCDD can stimulate induction of *sod1* by either the Nrf2 protein or the Ah receptor protein through the antioxidant responsive element (ARE) and xenobiotic responsive element (XRE), respectively [98]. This information suggests possible mechanisms for the adverse effect of xenobiotics on human health. FOXO3a, a member of the family of Forkhead transcription factors, can bind to the 5'-flanking region and mediate the expression of MnSOD resulting in protection of quiescent cells from oxidative stress [99]. Increased age-related Akt activity might be responsible for the phosphorylation and inactivation of FOXO3a, which in turn down-regulates MnSOD transcription [100]. Several putative FOXO transcription factor binding sites starting at positions -1376, -1231 and -822 have also been identified in the human *sod1* gene which suggests dual regulation by the pair NF- κ B/FOXO [45]. Knocking down peroxisome proliferator-activated receptor γ (PPAR γ) could also down-regulate MnSOD at the mRNA and protein levels and reduce the protective capability of MnSOD against oxidative damage in cardiomyocytes [101]. It is possible that a pathway crosstalk may exist between the nuclear receptor-regulated signaling cascade and the regulation of *sod2* gene expression.

The enzyme ECSOD contains copper and its activity directly correlates with the copper concentration and the copper chaperone antioxidant-1 (Atox1) [102]. Surprisingly, Atox1 not only acts as a copper chaperone involved in copper delivery to ECSOD at the trans-Golgi network but also positively regulates *sod3* gene transcription. For ECSOD to be active at a high level, it requires both the copper chaperone and transcription factor functions of Atox1 [18,102]. Menkes ATPase, a copper transporter, is also required for the activation of *sod3*, and modulated AngII induces hypertension and endothelial function by regulating ECSOD activity and vascular superoxide anion production [103,104]. In addition to being regulated by copper containing enzymes and transporters, the *sod3* gene is uniquely regulated negatively or positively by transcriptional repressors and enhancers. Repressors of *sod3* gene expression include myeloid zinc finger 1 and a gut-enriched Kruppel-like factor. Activators of *sod3* transcription include Ets family members such as Elf-1 and GA-binding protein α and β that actively interact with the mouse *sod3* purine-rich proximal promoter region to regulate the cell-type specific expression of mouse ECSOD [105]. Knowledge of positive and negative roles of these transcription factors may facilitate our understanding of *sods* expression under pathological conditions.

Epigenetic regulation of the *sod* genes

Epigenetic regulation refers to heritable changes in the level of gene expression not related to the underlying DNA sequence. Though cancer is clearly a genetic disease, either hereditary or somatic, epigenetic modulation may affect or contribute to carcinogenesis. It is well documented that malignant cancer often exhibits altered expression and activity of MnSOD compared with normal counterparts, but the reasons for this alteration are poorly defined. Doman's group published a series of papers that demonstrate the role of epigenetic regulation in increasing cytosine methylation and decreasing histone acetylation to create a repressive chromatin structure associated with epigenetic silencing of *sod2* expression in human breast

cancer cells and other transformed cells [106-108]. The relative expression patterns of MnSOD are inversely related to the methylation status of the *sod2* promoter in several pancreatic carcinoma cell lines. The methyltransferase inhibitor is able to reverse the hypermethylation status of CpG sites to restore MnSOD levels [109]. Similar observations indicating that the *sod2* gene is epigenetically silenced as a result of promoter hypermethylation have also been reported by others using KAS 6/1 human multiple myeloma cells [110]. In addition, early growth responsive-1 (Egr-1) interacts with Sp1 and histone deacetylase-1 (HDAC1) in the proximal promoter region of *sod2* to suppress histone acetylation and further inactivate MnSOD expression [111]. These publications provide insights into the possibility of an epigenetic mechanism for the regulation of the *sod2* gene.

Studies of the methylation status of the *sod1* gene in ALS patients have revealed that the promoter of the *sod1* gene was largely unmethylated in the subjects studied. Epigenetic silencing of *sod1* is therefore unlikely to be a common mechanism in ALS [112]. Though no difference in the methylation levels of CpG sites across the promoter region of the *sod3* gene has been found, it is possible that the activity of the *sod3* gene proximal promoter element may also be modulated by epigenetic processes [113]. Hypomethylation of the rabbit *sod3* gene has been associated with the development of atherosclerosis, suggesting that epigenetic modulation of *sod3* may be involved in the development of atherosclerotic lesions [114].

Post-transcriptional Regulation of the *sod* genes

It has been well-documented that specific gene expression is regulated not only at the transcriptional level but also at the post-transcriptional level by changes in mRNA stability, mRNA translation and post-translational modification. Thus, increased mRNA level may not be sufficient to compensate for a compromised translational deficiency. The presence of post-transcriptional regulation and RNA silencing pathways provides conserved mechanisms by which target gene expression could be rapidly modulated. Post-transcriptional processes such as mRNA processing, export and microRNA modulation form a complex regulatory network contributing to target gene expression patterns.

Because of the presence of the typical splice junction after the *sod2* gene is transcribed, human MnSOD mRNA is processed into two mRNA species of approximately 1 and 4kb size. A ~280-nucleotide fragment within the MnSOD mRNA coding region determines the stability of messenger RNA in the absence of ribosome transit, providing a mechanism for both basal and stimulus-dependent post-transcriptional regulation of MnSOD [115]. The Alu-like element contained in MnSOD mRNA 3'UTR acts as probable microRNA targets [116,117]. Moreover, mRNA binding with proteins and other RNAs may function as a critical regulator in post-transcriptional processes. Thus, predicting and identifying appropriate RNA structural motifs could provide insight into the regulatory mechanisms of gene expression [118]. A special, developmentally regulated MnSOD RNA-binding protein that is redox sensitive exists in rat lung and forms complexes with a fragment of the 3'UTR region of MnSOD mRNA [119]. RNA in polymers acts to inhibit MnSOD binding protein activity and prevent it from participating in post-transcriptional control of mature MnSOD protein product and activity [120,121]. On the other hand, the partially conserved 3'UTR cis-element in the *sod2* gene and RNA-protein binding activity are required for improving the translation of MnSOD. A translational enhancer in this 3'UTR cis-element, designated MnSOD-response element, is involved in the interaction with MnSOD RNA-binding protein to enhance translation efficiency and to increase translation of a heterologous RNA when it is positioned in a post-transcriptional reporter construct [122, 123]. Interestingly, tyrosine phosphorylation of this cytosolic MnSOD binding protein (MnSOD-BP) can modulate MnSOD protein level even though the identity of MnSOD-BP remains unknown [124]. The post-transcriptional mechanism will be another potentially important level of regulation defending mitochondria against oxidative stress-mediated injury.

Compared to the number of studies about *sod2*, studies of regulation mechanisms, such as post-transcriptional modulation of *sod1* and *sod3*, are relatively rare. Diverse 3'UTR lengths of *sod1* mRNA are associated with human Cu/ZnSOD enzyme activity [125]. Mutations in the 3'UTR of *sod1* in CNS tissue are associated with motor neuron disease [126]. The 10bp deletion in 3'UTR of the *sod3* transcript, which may be responsible for the alteration of ECSOD RNA half-life, has been described, but the significance and identity of the regulatory element remain unclear [127]. Given the potentially important role of ECSOD in defending against extracellular superoxide, additional studies of *sod3* gene activation and mRNA modification and processing should be useful for understanding the processes of superoxide dismutase-dependent diseases.

Biomedical implications

Cu/ZnSOD (*sod1*)

Cu/ZnSOD was the first superoxide dismutase in eukaryote to be characterized and it has been found in cytoplasm, nucleus, microsomes and also in the mitochondrial intermembrane space [9,128]. The discovery of the Cu/ZnSOD mutation in ALS, a fatal, adult-onset neurodegenerative disease primarily affecting motor neurons in the brain, brainstem, and spinal cord, has attracted broad attention [129]. Most current Cu/ZnSOD studies are focused on identification of the mutations in the coding region of the *sod1* gene and how the mutated *sod1* gene causes ALS and other neurodegenerative diseases. The focus at the protein level is due, in part, to the finding that ALS mice are not deficient in Cu/ZnSOD activity, but rather expression of mutant protein may lead to gain of toxic function. In addition, the promoter of the *sod1* gene is mostly unmethylated in familial ALS (fALS) patients, so epigenetic silencing of *sod1* is therefore unlikely to be a common mechanism in fALS [112]. The discovery of 11 missense *sod1* gene mutations in 13 familial ALSs by Rosen, *et al.* in 1993 provided the first molecular connection between Cu/ZnSOD and the pathogenesis of fALS [130]. At present, over 150 mutations distributed in coding regions of the *sod1* gene, affecting over 70 positions, have been reported [131]. Updated information about these mutations is available at the ALS online database (<http://alsod.iop.kcl.ac.uk/Als/index.aspx>) [132]. The majority of known mutations are missense mutations distributed among five exons of the *sod1* gene. A newly identified mutation with a defect in the TATA box of the *sod1* promoter has been reported, but genetic analysis has revealed that it is not a disease-causing mutation or susceptibility factor for ALS [133]. Several mutations of highly diverse properties cause the same clinical outcomes, but the precise mechanism of how each mutation in the *sod1* gene leads to neurodegeneration remains unclear. The Ala4Val mutation in exon1 in humans is the most frequent mutation found from both extensive screening results of the *sod1* coding region and clinical experiences in the U.S. [130]. However, the type and relative frequency of each mutation vary in the world population. Although mutant Cu/ZnSOD-catalyzed oxidative reactions and/or misfolding are being proposed as driving fALS pathogenesis [131], mice deficient for *sod1* are viable and appear to develop without obvious motor abnormalities, suggesting that “gain-of-function” mutations in *sod1* may be a major factor causing fALS. A number of transgenic rodent models with different point mutations in the *sod1* gene have been developed. Rodents carrying the G93A *sod1* gene mutation are the most extensively studied despite the fact that this mutation is rarely detected in humans. Whether the information harvested from animal models can be appropriately applied to humans requires careful genetic comparison between different species. It has been found that accumulation and aggregation of insoluble Cu/ZnSOD exist in motor neurons of fALS patients and transgenic animal models with designed *sod1* mutations such as G93A and G37R. These mutations cause inhibition of axonal transport and mitochondrial dysfunction [134,135]. Excellent reviews of the catalytic activity of mutant Cu/ZnSOD, *in vivo* metallation state and stability, as well as oxidative modification related to *sod1*-associated fALS, have been written [131,136].

For the Cu/ZnSOD enzyme, the copper ion functions in the oxidized and reduced alternation while the Zn^{2+} helps maintain enzyme stability [11,137]. The copper chaperone for SOD (CCS), which has been suggested as a robust, sensitive and specific biomarker of copper status, delivers copper to the Cu/ZnSOD apoenzyme [12]. The CCS-knockout mice serve as a resource for studying alternative copper source for Cu/ZnSOD [138]. It has been shown that CCS facilitates the stepwise conversion of the disulfide-reduced immature Cu/ZnSOD to the active disulfide-containing enzyme [139,140]. Thus, copper related post-translational regulation may affect enzyme activation, folding and aggregation leading to aberrant protein function in diseases, especially in fALS. In addition to copper zinc being a multipurpose trace element, it contributes to Cu/ZnSOD structure and modulates the folding free energy surface of the enzyme [14]. The potential role of zinc-binding proteins, such as metallothioneins and zinc transporter (ZnT), in delivering metal ions to enzymes has been suggested but remains to be established. Appropriate copper and zinc accessibility to Cu/ZnSOD can influence the structural geometry and its redox activity, as well as the protein function. Decreased zinc affinity of ALS-mutant SOD can lead to elevation of peroxynitrite-mediated tyrosine nitration [141]. Zinc-deficiency in either wild-type or ALS-mutant SOD exhibits nitric oxide-dependent neurons apoptosis, a process which can be prevented by zinc repletion [142]. Structural analysis of constitutively zinc-deficient SOD protein generated by mutation in zinc-binding pocket identifies asymmetric dimers with weakened dimer interface, enhanced redox properties of the copper and thiol-dependent aggregation of zinc-deficient SOD [143]. However, whether supplement of zinc will be beneficial to ALS patient is unknown. Zn supplementation in ALS mice has either protective or toxic effect depending on the levels of dietary Zinc [144,145]. Therefore, considering this paradoxically dose-dependent effect, Zinc supplementation in ALS patient will require information on the zinc status of individual patient.

In addition to fALS, alteration of Cu/ZnSOD expression level or catalytic activity has been identified in several physiological situations such as aging and age-associated diseases (reviewed in [11,146,147]). *Sod1* knock-out mice have been shown to suffer from physiological impairment including reduced female fertility, macular degeneration and death from liver tumors [131,136]. Considering the important role of Cu/ZnSOD in these diseases, and the fact that the majority of ALS is sporadic, future studies should include understanding the regulation of *sod1* gene expression and post-translational modifications.

MnSOD (*sod2*)

Abnormal cellular redox status has been associated with many types of diseases. Among three SOD isoforms, MnSOD is the only SOD that has proved to be essential for the survival of aerobic organisms [148]. The physiological role of MnSOD as a cytoprotective enzyme has been clearly confirmed by the extremely short life-span of MnSOD knockout mice, which died shortly after birth with dilated cardiomyopathy and neurodegeneration [149,150]. The importance of MnSOD beyond the need for survival in the aerobic environment has also been well-established. For example, in the development of cancer, which involves either the activation of oncogenes or the inactivation of the tumor suppressor gene, the levels of ROS and superoxide dismutase are regulated reciprocally. It has been demonstrated that, at an early stage of cancer development, oxidative stress and relatively low levels of antioxidant enzymes result in DNA damage and cell injury. Because MnSOD plays a critical role in the defense against oxidant-induced injury and apoptosis of rapidly growing cancer cells, it is considered a unique tumor suppressor protein [151]. The tumor suppressive effect of MnSOD has been demonstrated in numerous cell types with malignant phenotype via modulating redox-related transcriptional factors (reviewed in [152]). However, after cancer has progressed, the expression of MnSOD can be higher in aggressive cancer compared to benign counterparts. These findings have been reported for advanced cancer tissues and blood samples of leukemia. Significantly higher MnSOD levels in malignant ovarian cancer tissue compared to normal

ovarian epithelium and benign lesions have also been identified in a large number of samples using comparative tissue microarray analysis [153,154]. ROS partially renders cancer cells more dependent on the function of superoxide dismutase to protect itself from damage caused by increased amounts of superoxide radicals. The necessity to alleviate ROS stress, coupled to the loss of MnSOD suppressors as the cancer progresses, provides a mechanistic explanation for a high MnSOD level in some cancer types at advanced stages. Due to the pivotal role of mitochondria and MnSOD in regulating cell death and cancer development, alteration of MnSOD activity and levels could be a potential target for therapeutic intervention.

A number of studies have identified the association of *sod2* genetic polymorphisms with various diseases including type II diabetes and hypertension [159-162]. The presence of MnSOD single nucleotide polymorphisms (SNPs) and the potential effects of these SNPs on human MnSOD have been briefly reviewed [163] and are summarized in Table 2. Mutations detected in the *sod2* promoter region reveal the possibility for decreased expression of MnSOD in several human cancer cells [155]. Among these mutations, C to T transition at -102 and an A insertion at -93 interrupting the single-strand loop structure have been suggested as reasons for reduced levels of MnSOD activity in some tumor cell lines. These mutations create an extra DNA binding site for the transcription factor AP-2 and alter sequence-specific interaction between DNA-protein and protein-protein in the transcription initiation complex [75,155]. C to G transversion at -38 modulates an AP-2 dependent dysregulation of *sod2* gene expression [85].

The newly synthesized polypeptide for MnSOD requires that it be transported across two mitochondrial membranes into the mitochondrial matrix where the enzyme is converted to an active form. This transport activity is mediated by the presence of a signal sequence within the N-terminal of the polypeptide. An extensively investigated cytosine to thymine (C to T) single nucleotide polymorphism in the *sod2* mitochondrial targeting sequence, which causes the substitution of alanine (GCT) with valine (GTT) at codon 16, can disrupt the secondary α -helix structure of MnSOD and affect the localization and efficiency of mitochondrial transport of MnSOD enzyme [156]. Sutton *et al.* have reported that the MnSOD Ala variant generates 30-40% more active MnSOD enzyme and allows more efficient MnSOD import into the mitochondrial matrix than its Val counterpart, suggesting that the homozygous AA genotype may have higher MnSOD activity than its VV counterpart [164]. This target sequence polymorphism of human MnSOD gene and its association with cancer risk have been recently reviewed [165]. With respect to the AA genotype having a beneficial role in higher MnSOD activity, indeed, the *sod2* homozygous variant genotype (Val/Val) has been associated with a greater risk of pancreatic cancer compared with the Ala allele. The occurrence of the VV variant also enhances the risk of non-small cell lung carcinoma in the presence of p53 and XRCC1 polymorphism [166,167]. However, there is significant variability in results regarding the association of Ala16Val polymorphism with increased risk of disease. Little overall association has been found between MnSOD polymorphism and other diseases, such as asthma, Parkinson's disease, lung cancer and prostate cancer [162,168-171]. Some studies demonstrate that the AA genotype elicits increased cancer risk. The Finnish study of male heavy smokers found that the MnSOD AA polymorphism was significantly associated with higher risk of prostate cancer, especially for tumors with higher Gleason score [172]. S. H. Olson and colleagues also found that carriers of the AA genotype had greater risk for ovarian carcinoma. Similar results have been described in breast cancer studies [173]. These reports indicate that this polymorphism may be functionally neutral. However, these studies do not delineate the levels of corresponding factors, such as the loss of p53 or AP-2. The variability of sample characteristics and disease stages may contribute to the discrepancies among studies even on the same type of disease [170,172]. Thus, extensive, population-based, age-matched, case-control studies will be required to thoroughly investigate Ala16Val polymorphism so as to provide more reliable information for prevention, treatment and surveillance.

Another potentially important polymorphic substitution for isoleucine or threonine is found at amino acid 58 in the mature human MnSOD protein. The Thr variant is less stable and more susceptible to inactivation by S-thiolation reaction than the Ile counterpart due to its stability at the tetrameric interface [157]. Consistent with the tumor suppressive role of MnSOD, human malignant breast cancer cells overexpressing Ile58 MnSOD have 3-fold higher MnSOD activity and a greater tumor-suppressive effect than cells overexpressing the Thr58 counterpart at an equal MnSOD protein level [174]. Further direct testing of this possibility would be to replace cellular MnSOD with either version and then to study the effect on tumorigenesis, e.g., in a transgenic knockin model. Another relatively unique point mutation, C5782T in exon3 of *sod2* producing a L60F mutation in the mature enzyme, has been found in Jurkat T lymphocytes. The L60F mutation led to a deficiency in MnSOD activity and correlated with the malignant phenotype. This finding also explains the paradoxical effects of thiol reagents on antioxidants in some leukemia cells [158]. The different roles that MnSOD plays at different cancer stages suggest that specific strategies will be needed for specific situations. Thus, understanding how the expression of MnSOD can be selectively regulated at each stage of cancer development is likely to have important implications for the prevention and treatment of cancer.

ECSOD (*sod3*)

This copper- and zinc-containing dismutase, extracellular superoxide dismutase (ECSOD), was first discovered in extracellular fluids including human plasma, lymph, and synovial fluid by Marklund, *et al.* in 1982 [175-177]. ECSOD is the least characterized SOD of the three SOD isoforms. It is a secreted hydrophobic glycoprotein usually existing as a homotetramer with an approximate molecular weight of 135,000 Da [175]. After removal of the signal peptide, mature ECSOD protein is composed of three domains: the amino-terminal domain containing glycosylation sites, an active site domain that shows strong homology with Cu/ZnSOD and a short carboxyl-terminal domain [38]. One unique characteristic of ECSOD that was identified during initial purification is its strong affinity for heparin and other heparin sulfates, the interaction of which was further localized to the C-terminal, the positively charged, heparin-binding domain of ECSOD [178,179]. The polycationic matrix-binding domain makes ECSOD directly bind to hyaluronan and inhibit oxidant-induced degradation of this glycosaminoglycan so as to prevent inflammation in response to lung injury [180]. A common human *sod3* gene variant (substitution of arginine 213 with glycine R213G), which is located in the center of the carboxyl-terminal cluster of positively charged amino acid residues of the heparin-binding domain, has been described [181-183]. Due to impaired heparin and collagen binding affinities, this variant is considered to be related to increased plasma ECSOD concentration but not to enzymatic activity [181]. The significance of this polymorphism varies depending on the disease and population [184,185]. The association between the R213G ECSOD polymorphism and clinical significance has been summarized in several reviews of ECSOD [20,42,183]. Additional variants of the human *sod3* gene include 4 other missense mutations, Ala40Thr, Phe131Cys, Val160Leu and Arg202Leu. A silent mutation, Leu53Leu (CTG to TTG), has been found in samples of Japanese and Mediterranean populations [183-185]. However, the functional significance of most of these new variants on metabolic activity and disease incidence requires further investigation.

Interestingly, the human ECSOD polypeptide folds in two distinct ways with different disulfide bridge patterns resulting in enzymatically active (aECSOD) and inactive (iECSOD) subunits [186-188]. Thus, differential modification of different disulfide bonds, intracellular folding and proteolytic processing of protein also contribute importantly to the levels of enzymatic activity.

The expression of ECSOD and its catalytic activity have been associated with a variety of diseases including cardiovascular, neurological disorders and pulmonary diseases. Several regulatory mechanisms have been proposed [42]. It has been shown that ECSOD is a main regulator of nitric oxide (NO) bioavailability and bioactivity by modulating generation of the toxic product peroxynitrite in the vasculature [189]. ECSOD binding to protein filbulin-5 maintains vascular $O_2^{\cdot-}$ levels [187,190]. Our focus is on the molecular mechanism known to regulate *sod3* gene expression and the related biomedical implication. Thus, because ECSOD activity and function and methods or applications of *sod3* gene transfer have all been described elegantly in other reviews, they will not be presented here [20,42,177,183]. Despite the availability of several disease models related to ECSOD, the precise mechanism for the control of ECSOD expression is unknown. Understanding the molecular mechanisms involved in the regulation of *sod3* gene expression and the factors involved in tissue and cell-specific expression of the *sod3* gene will be important for therapeutic attempts to design novel strategies for controlling ECSOD- related tissue injury.

Conclusions and Future Directions

The essential role of SODs in the survival of aerobic organisms and prevention of pathological conditions demonstrates the significance of understanding how the expression of these genes can be regulated. At the transcription level, an individual *sod* gene has its own unique regulatory mechanisms and also uses common transcriptional factors. These features provide the opportunity to either selectively alter the expression of a *sod* gene or concurrently modulate all of them as a family. In addition to transcriptional control, epigenetic regulation and post-transcriptional modifications can also play important roles in controlling the level of functional SODs. These processes include stabilizing SOD mRNAs and regulating their translation. Considering the current explosion of microRNA studies and the roles of microRNA in diseases, future studies should also emphasize regulation of SOD translation by microRNA. Due to the importance of metal cofactors to the activity of superoxide dismutase, the processes and effects of metal ion insertion on SOD function deserve further in-depth investigations. Because the compartmental localization of each SOD is different in sub-cellular compartments, approaches to target their site-specific expression will be very important and could be used to aid the development of novel SOD-dependent therapeutic strategies.

Acknowledgments

Work for this review was supported by NIH grants CA 49797 and CA 73599.

Abbreviations

ROS	Reactive oxygen species
$O_2^{\cdot-}$	Superoxide
$\cdot OH$	Hydroxyl radical
H_2O_2	Hydrogen peroxide
RNS	Reactive nitrogen species
SOD	

	Superoxide dismutase
Cu/ZnSOD	Copper-zinc superoxide dismutase
MnSOD	Manganese superoxide dismutase
ECSOD	Extracellular superoxide dismutase
ALS	Amyotrophic Lateral Sclerosis
NF-κB	Nuclear Factor-KappaB
Sp1	Specificity Protein 1
AP-1	Activator Protein 1
AP-2	Activating Protein 2
C/EBP	CCAAT Enhancer-Binding Proteins
PI3K	Phosphoinositide 3-kinases
TPA	12-O-tetradecanoylphorbol-13-acetate
IFN-γ	Interferon-gamma
TNF α	Tumor necrosis factor α
IL-1	Interleukin-1beta
IL-4	Interleukin-4
IL-6	Interleukin-6
iNOS	Inducible nitric oxide synthase
Egr-1	Early growth response factor 1
nNOS	Neuronal nitric oxide synthase

PIN*POINT	Protein Position Identification with Nuclease Tail
NPM	Nucleophosmin
TSA	Trichostatin A
MAPK	Mitogen-activated protein kinases
JNK	c-Jun N-terminal kinases
PPRE	Peroxisome proliferator-responsive element
Elk-1	E-26 like protein 1
YY1	Yin Yang 1
ARE	Antioxidant responsive element
XRE	Xenobiotic responsive element
FOXO3	Forkhead box O3
PPAR γ	Peroxisome proliferator-activated receptor γ
Atox1	Antioxidant-1
Ang II	Angiotensin II
HDAC1	Histone deacetylase-1
MnSOD-BP	MnSOD binding protein
fALS	familial Amyotrophic Lateral Sclerosis
ZnT	Zinc transporter
SNP	Single nucleotide polymorphism

References

1. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. *Mutat Res* 2004;567:1–61. [PubMed: 15341901]
2. Chen AF, Davies CM, De Lin M, Fermor B. Oxidative DNA damage in osteoarthritic porcine articular cartilage. *J Cell Physiol* 2008;217:828–833. [PubMed: 18720406]
3. Xie L, Zhu X, Hu Y, Li T, Gao Y, Shi Y, Tang S. Mitochondrial DNA oxidative damage triggering mitochondrial dysfunction and apoptosis in high glucose-induced HRECs. *Invest Ophthalmol Vis Sci* 2008;49:4203–4209. [PubMed: 18539942]
4. Sun Y, Oberley LW. Redox regulation of transcriptional activators. *Free Radic Biol Med* 1996;21:335–348. [PubMed: 8855444]
5. Cai J, Yang J, Jones DP. Mitochondrial control of apoptosis: the role of cytochrome c. *Biochim Biophys Acta* 1998;1366:139–149. [PubMed: 9714780]
6. Giannattasio S, Atlante A, Antonacci L, Guaragnella N, Lattanzio P, Passarella S, Marra E. Cytochrome c is released from coupled mitochondria of yeast en route to acetic acid-induced programmed cell death and can work as an electron donor and a ROS scavenger. *FEBS Lett* 2008;582:1519–1525. [PubMed: 18396162]
7. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1 α -Kv1.5 O₂-sensing pathway at the intersection of pulmonary hypertension and cancer. *Am J Physiol Heart Circ Physiol* 2008;294:H570–578. [PubMed: 18083891]
8. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. *Trends Cell Biol* 2007;17:422–427. [PubMed: 17804237]
9. McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocyte hemocuprein. *J Biol Chem* 1969;244:6049–6055. [PubMed: 5389100]
10. Parge HE, Hallewell RA, Tainer JA. Atomic structures of wild-type and thermostable mutant recombinant human Cu,Zn superoxide dismutase. *Proc Natl Acad Sci U S A* 1992;89:6109–6113. [PubMed: 1463506]
11. Fridovich I. Superoxide radical and superoxide dismutases. *Annu Rev Biochem* 1995;64:97–112. [PubMed: 7574505]
12. Harvey LJ, McArdle HJ. Biomarkers of copper status: a brief update. *Br J Nutr* 2008;99:S10–13. [PubMed: 18598583]
13. Carroll MC, Girouard JB, Ulloa JL, Subramaniam JR, Wong PC, Valentine JS, Culotta VC. Mechanisms for activating Cu- and Zn-containing superoxide dismutase in the absence of the CCS Cu chaperone. *Proc Natl Acad Sci U S A* 2004;101:5964–5969. [PubMed: 15069187]
14. Kayatekin C, Zitzewitz JA, Matthews CR. Zinc binding modulates the entire folding free energy surface of human Cu,Zn superoxide dismutase. *J Mol Biol* 2008;384:540–555. [PubMed: 18840448]
15. Luk EE, Culotta VC. Manganese superoxide dismutase in *Saccharomyces cerevisiae* acquires its metal co-factor through a pathway involving the Nramp metal transporter, Smf2p. *J Biol Chem* 2001;276:47556–47562. [PubMed: 11602606]
16. Luk E, Carroll M, Baker M, Culotta VC. Manganese activation of superoxide dismutase 2 in *Saccharomyces cerevisiae* requires MTM1, a member of the mitochondrial carrier family. *Proc Natl Acad Sci U S A* 2003;100:10353–10357. [PubMed: 12890866]
17. Luk E, Yang M, Jensen LT, Bourbonnais Y, Culotta VC. Manganese activation of superoxide dismutase 2 in the mitochondria of *Saccharomyces cerevisiae*. *J Biol Chem* 2005;280:22715–22720. [PubMed: 15851472]
18. Itoh S, Ozumi K, Kim HW, Nakagawa O, McKinney RD, Folz RJ, Zelko IN, Ushio-Fukai M, Fukai T. Novel mechanism for regulation of extracellular SOD transcription and activity by copper: Role of antioxidant-1. *Free Radic Biol Med* 2009;46:95–104. [PubMed: 18977292]
19. Qin Z, Gongora MC, Ozumi K, Itoh S, Akram K, Ushio-Fukai M, Harrison DG, Fukai T. Role of Menkes ATPase in Angiotensin II-Induced Hypertension. A Key Modulator for Extracellular Superoxide Dismutase Function. *Hypertension*. 2008

20. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. *Free Radic Biol Med* 2002;33:337–349. [PubMed: 12126755]
21. Forman HJ. Use and abuse of exogenous H₂O₂ in studies of signal transduction. *Free Radic Biol Med* 2007;42:926–932. [PubMed: 17349920]
22. Liu B, Chen Y, St Clair DK. ROS and p53: a versatile partnership. *Free Radic Biol Med* 2008;44:1529–1535. [PubMed: 18275858]
23. Kalmar B, Novoselov S, Gray A, Cheetham ME, Margulis B, Greensmith L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1(G93A) mouse model of ALS. *J Neurochem*. 2008
24. Joseph A, L Y, Koo HC, Davis JM, Pollack S, Kazzaz JA. Superoxide dismutase attenuates hyperoxia-induced interleukin-8 induction via AP-1. *Free radical biology & medicine*. 2008
25. Pawlak K, Domaniewski T, Mysliwiec M, Pawlak D. The kynurenines are associated with oxidative stress, inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease. *Atherosclerosis*. 2008
26. Kaewpila S, Venkataraman S, Buettner GR, Oberley LW. Manganese superoxide dismutase modulates hypoxia-inducible factor-1 alpha induction via superoxide. *Cancer Res* 2008;68:2781–2788. [PubMed: 18413745]
27. Oberley LW. Anticancer therapy by overexpression of superoxide dismutase. *Antioxid Redox Signal* 2001;3:461–472. [PubMed: 11491657]
28. Hsu JL, Visner GA, Burr IA, Nick HS. Rat copper/zinc superoxide dismutase gene: isolation, characterization, and species comparison. *Biochem Biophys Res Commun* 1992;186:936–943. [PubMed: 1379810]
29. Schmutz SM, Cornwell D, Moker JS, Troyer DL. Physical mapping of SOD1 to bovine chromosome 1. *Cytogenet Cell Genet* 1996;72:37–39. [PubMed: 8565629]
30. Levanon D, Lieman-Hurwitz J, Dafni N, Wigderson M, Sherman L, Bernstein Y, Laver-Rudich Z, Danciger E, Stein O, Groner Y. Architecture and anatomy of the chromosomal locus in human chromosome 21 encoding the Cu/Zn superoxide dismutase. *EMBO J* 1985;4:77–84. [PubMed: 3160582]
31. Jones PL, Kucera G, Gordon H, Boss JM. Cloning and characterization of the murine manganese superoxide dismutase-encoding gene. *Gene* 1995;153:155–161. [PubMed: 7875582]
32. DiSilvestre D, Kleeberger SR, Johns J, Levitt RC. Structure and DNA sequence of the mouse MnSOD gene. *Mamm Genome* 1995;6:281–284. [PubMed: 7613035]
33. Ho YS, Howard AJ, Crapo JD. Molecular structure of a functional rat gene for manganese-containing superoxide dismutase. *Am J Respir Cell Mol Biol* 1991;4:278–286. [PubMed: 2001291]
34. Meyrick B, Magnuson MA. Identification and functional characterization of the bovine manganese superoxide dismutase promoter. *Am J Respir Cell Mol Biol* 1994;10:113–121. [PubMed: 8292376]
35. Marlhens F, Nicole A, Sinet PM. Lowered level of translatable messenger RNAs for manganese superoxide dismutase in human fibroblasts transformed by SV 40. *Biochem Biophys Res Commun* 1985;129:300–305. [PubMed: 2988549]
36. Wan XS, Devalaraja MN, St Clair DK. Molecular structure and organization of the human manganese superoxide dismutase gene. *DNA Cell Biol* 1994;13:1127–1136. [PubMed: 7702755]
37. Hjalmarsson K, Marklund SL, Engstrom A, Edlund T. Isolation and sequence of complementary DNA encoding human extracellular superoxide dismutase. *Proc Natl Acad Sci U S A* 1987;84:6340–6344. [PubMed: 3476950]
38. Folz RJ, Crapo JD. Extracellular superoxide dismutase (SOD3): tissue-specific expression, genomic characterization, and computer-assisted sequence analysis of the human EC SOD gene. *Genomics* 1994;22:162–171. [PubMed: 7959763]
39. Perry AC, Jones R, Hall L. Isolation and characterization of a rat cDNA clone encoding a secreted superoxide dismutase reveals the epididymis to be a major site of its expression. *Biochem J* 1993;293 (Pt 1):21–25. [PubMed: 8328962]
40. Folz RJ, Guan J, Seldin MF, Oury TD, Enghild JJ, Crapo JD. Mouse extracellular superoxide dismutase: primary structure, tissue-specific gene expression, chromosomal localization, and lung in situ hybridization. *Am J Respir Cell Mol Biol* 1997;17:393–403. [PubMed: 9376114]

41. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. *Oncogene* 2006;25:6706–6716. [PubMed: 17072323]
42. Fattman CL, Schaefer LM, Oury TD. Extracellular superoxide dismutase in biology and medicine. *Free Radic Biol Med* 2003;35:236–256. [PubMed: 12885586]
43. Xu Y, Kiningham KK, Devalaraja MN, Yeh CC, Majima H, Kasarskis EJ, St Clair DK. An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. *DNA Cell Biol* 1999;18:709–722. [PubMed: 10492402]
44. Minc E, de Coppet P, Masson P, Thiery L, Dutertre S, Amor-Gueret M, Jaulin C. The human copper-zinc superoxide dismutase gene (SOD1) proximal promoter is regulated by Sp1, Egr-1, and WT1 via non-canonical binding sites. *J Biol Chem* 1999;274:503–509. [PubMed: 9867871]
45. Rojo AI, Salinas M, Martin D, Perona R, Cuadrado A. Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. *J Neurosci* 2004;24:7324–7334. [PubMed: 15317858]
46. Mumbengegwi DR, Li Q, Li C, Bear CE, Engelhardt JF. Evidence for a superoxide permeability pathway in endosomal membranes. *Mol Cell Biol* 2008;28:3700–3712. [PubMed: 18378695]
47. Dimayuga FO, Wang C, Clark JM, Dimayuga ER, Dimayuga VM, Bruce-Keller AJ. SOD1 overexpression alters ROS production and reduces neurotoxic inflammatory signaling in microglial cells. *J Neuroimmunol* 2007;182:89–99. [PubMed: 17097745]
48. Beni SM, Tsenter J, Alexandrovich AG, Galron-Krool N, Barzilai A, Kohen R, Grigoriadis N, Simeonidou C, Shohami E. CuZn-SOD deficiency, rather than overexpression, is associated with enhanced recovery and attenuated activation of NF-kappaB after brain trauma in mice. *J Cereb Blood Flow Metab* 2006;26:478–490. [PubMed: 16094314]
49. Eastgate J, Moreb J, Nick HS, Suzuki K, Taniguchi N, Zucali JR. A role for manganese superoxide dismutase in radioprotection of hematopoietic stem cells by interleukin-1. *Blood* 1993;81:639–646. [PubMed: 8427959]
50. Akashi M, Hachiya M, Paquette RL, Osawa Y, Shimizu S, Suzuki G. Irradiation increases manganese superoxide dismutase mRNA levels in human fibroblasts. Possible mechanisms for its accumulation. *J Biol Chem* 1995;270:15864–15869. [PubMed: 7797591]
51. Fujii J, Taniguchi N. Phorbol ester induces manganese-superoxide dismutase in tumor necrosis factor-resistant cells. *J Biol Chem* 1991;266:23142–23146. [PubMed: 1744113]
52. Harris CA, Derbin KS, Hunte-McDonough B, Krauss MR, Chen KT, Smith DM, Epstein LB. Manganese superoxide dismutase is induced by IFN-gamma in multiple cell types. Synergistic induction by IFN-gamma and tumor necrosis factor or IL-1. *Journal of Immunology* 1991;147:149–154.
53. Wong GH, Elwell JH, Oberley LW, Goeddel DV. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. *Cell* 1988;58:923–931. [PubMed: 2476237]
54. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. *Science* 1988;242:941–944. [PubMed: 3263703]
55. Visner GA, Dougall WC, Wilson JM, Burr IA, Nick HS. Regulation of manganese superoxide dismutase by lipopolysaccharide, interleukin-1, and tumor necrosis factor. Role in the acute inflammatory response. *J Biol Chem* 1990;265:2856–2864. [PubMed: 2406241]
56. Dougall WC, Nick HS. Manganese superoxide dismutase: a hepatic acute phase protein regulated by interleukin-6 and glucocorticoids. *Endocrinology* 1991;129:2376–2384. [PubMed: 1718727]
57. St Clair DK, Porntadavity S, Xu Y, Kiningham K. Transcription regulation of human manganese superoxide dismutase gene. *Methods Enzymol* 2002;349:306–312. [PubMed: 11912921]
58. Kiningham KK, Xu Y, Daosukho C, Popova B, St Clair DK. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. *Biochem J* 2001;353:147–156. [PubMed: 11115408]
59. Guo Z, Boekhoudt GH, Boss JM. Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganous superoxide dismutase. *J Biol Chem* 2003;278:23570–23578. [PubMed: 12684509]

60. Rogers RJ, Chesrown SE, Kuo S, Monnier JM, Nick HS. Cytokine-inducible enhancer with promoter activity in both the rat and human manganese-superoxide dismutase genes. *Biochem J* 2000;347(Pt 1):233–242. [PubMed: 10727424]
61. Dhar SK, Xu Y, Noel T, St Clair DK. Chronic exposure to 12-O-tetradecanoylphorbol-13-acetate represses sod2 induction in vivo: the negative role of p50. *Carcinogenesis* 2007;28:2605–2613. [PubMed: 17652337]
62. Marklund SL. Regulation by cytokines of extracellular superoxide dismutase and other superoxide dismutase isoenzymes in fibroblasts. *J Biol Chem* 1992;267:6696–6701. [PubMed: 1551878]
63. Brady TC, Chang LY, Day BJ, Crapo JD. Extracellular superoxide dismutase is upregulated with inducible nitric oxide synthase after NF-kappa B activation. *Am J Physiol* 1997;273:L1002–1006. [PubMed: 9374727]
64. Dynan WS, Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. *Cell* 1983;35:79–87. [PubMed: 6313230]
65. Briggs MR, Kadonaga JT, Bell SP, Tjian R. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. *Science* 1986;234:47–52. [PubMed: 3529394]
66. Dynan WS, Tjian R. Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. *Cell* 1983;32:669–680. [PubMed: 6187469]
67. Xu Y, Porntadavity S, St Clair DK. Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). *Biochem J* 2002;362:401–412. [PubMed: 11853549]
68. Yeh CC, Wan XS, St Clair DK. Transcriptional regulation of the 5' proximal promoter of the human manganese superoxide dismutase gene. *DNA Cell Biol* 1998;17:921–930. [PubMed: 9839801]
69. Seo SJ, Kim HT, Cho G, Rho HM, Jung G. Sp1 and C/EBP-related factor regulate the transcription of human Cu/Zn SOD gene. *Gene* 1996;178:177–185. [PubMed: 8921911]
70. Afonso V, Santos G, Collin P, Khatib AM, Mitrovic DR, Lomri N, Leitman DC, Lomri A. Tumor necrosis factor-alpha down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway. *Free Radic Biol Med* 2006;41:709–721. [PubMed: 16895791]
71. Baldelli S, Aquilano K, Rotilio G, Ciriolo MR. Glutathione and copper, zinc superoxide dismutase are modulated by overexpression of neuronal nitric oxide synthase. *Int J Biochem Cell Biol* 2008;40:2660–2670. [PubMed: 18586551]
72. Tanaka T, Kurabayashi M, Aihara Y, Ohyama Y, Nagai R. Inducible expression of manganese superoxide dismutase by phorbol 12-myristate 13-acetate is mediated by Sp1 in endothelial cells. *Arterioscler Thromb Vasc Biol* 2000;20:392–401. [PubMed: 10669635]
73. Kuo S, Chokas AL, Rogers RJ, Nick HS. PIN*POINT analysis on the endogenous MnSOD promoter: specific demonstration of Sp1 binding in vivo. *Am J Physiol Cell Physiol* 2003;284:C528–534. [PubMed: 12388080]
74. Mastrangelo IA, Courey AJ, Wall JS, Jackson SP, Hough PV. DNA looping and Sp1 multimer links: a mechanism for transcriptional synergism and enhancement. *Proc Natl Acad Sci U S A* 1991;88:5670–5674. [PubMed: 2062845]
75. Xu Y, Fang F, Dhar SK, St Clair WH, Kasarskis EJ, St Clair DK. The role of a single-stranded nucleotide loop in transcriptional regulation of the human sod2 gene. *J Biol Chem* 2007;282:15981–15994. [PubMed: 17426024]
76. Dhar SK, Xu Y, Chen Y, St Clair DK. Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. *J Biol Chem* 2006;281:21698–21709. [PubMed: 16740634]
77. Zelko IN, Folz RJ. Sp1 and Sp3 transcription factors mediate trichostatin A-induced and basal expression of extracellular superoxide dismutase. *Free Radic Biol Med* 2004;37:1256–1271. [PubMed: 15451065]
78. Zelko IN, Mueller MR, Folz RJ. Transcription factors sp1 and sp3 regulate expression of human extracellular superoxide dismutase in lung fibroblasts. *Am J Respir Cell Mol Biol* 2008;39:243–251. [PubMed: 18314536]
79. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim Biophys Acta* 1991;1072:129–157. [PubMed: 1751545]

80. Huang CY, Fujimura M, Chang YY, Chan PH. Overexpression of copper-zinc superoxide dismutase attenuates acute activation of activator protein-1 after transient focal cerebral ischemia in mice. *Stroke* 2001;32:741–747. [PubMed: 11239196]
81. Zhou W, Zhang Y, Hosch MS, Lang A, Zwacka RM, Engelhardt JF. Subcellular site of superoxide dismutase expression differentially controls AP-1 activity and injury in mouse liver following ischemia/reperfusion. *Hepatology* 2001;33:902–914. [PubMed: 11283855]
82. Zhao Y, Oberley TD, Chaiswing L, Lin SM, Epstein CJ, Huang TT, St Clair D. Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model. *Oncogene* 2002;21:3836–3846. [PubMed: 12032821]
83. Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, Schaack J, Simon FR. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. *Biochem J* 2004;378:919–928. [PubMed: 14670077]
84. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. *Genome Biol* 2005;6:246. [PubMed: 16420676]
85. Xu Y, Fang F, Dhar SK, Bosch A, St Clair WH, Kasarskis EJ, St Clair DK. Mutations in the SOD2 Promoter Reveal a Molecular Basis for an Activating Protein 2-Dependent Dysregulation of Manganese Superoxide Dismutase Expression in Cancer Cells. *Mol Cancer Res* 2008;6:1881–1893. [PubMed: 19074833]
86. Kim YH, Park KH, Rho HM. Transcriptional activation of the Cu,Zn-superoxide dismutase gene through the AP2 site by ginsenoside Rb2 extracted from a medicinal plant, *Panax ginseng*. *J Biol Chem* 1996;271:24539–24543. [PubMed: 8798715]
87. Zhu C, Huang Y, Weydert CJ, Oberley LW, Domann FE. Constitutive activation of transcription factor AP-2 is associated with decreased MnSOD expression in transformed human lung fibroblasts. *Antioxid Redox Signal* 2001;3:387–395. [PubMed: 11491651]
88. Zhu CH, Huang Y, Oberley LW, Domann FE. A family of AP-2 proteins down-regulate manganese superoxide dismutase expression. *J Biol Chem* 2001;276:14407–14413. [PubMed: 11278550]
89. Huang Y, Peng J, Oberley LW, Domann FE. Transcriptional inhibition of manganese superoxide dismutase (SOD2) gene expression by DNA methylation of the 5' CpG island. *Free Radic Biol Med* 1997;23:314–320. [PubMed: 9199894]
90. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. *Biochem J* 2002;365:561–575. [PubMed: 12006103]
91. Seo SJ, Kang SS, Cho G, Rho HM, Jung G. C/EBP alpha and C/EBPbeta play similar roles in the transcription of the human Cu/Zn SOD gene. *Gene* 1997;203:11–15. [PubMed: 9426001]
92. Kim YH, Yoo HY, Chang MS, Jung G, Rho HM. C/EBP alpha is a major activator for the transcription of rat Cu/Zn superoxide dismutase gene in liver cell. *FEBS Lett* 1997;401:267–270. [PubMed: 9013901]
93. Qiu X, Aiken KJ, Chokas AL, Beachy DE, Nick HS. Distinct functions of CCAAT enhancer-binding protein isoforms in the regulation of manganese superoxide dismutase during interleukin-1beta stimulation. *J Biol Chem* 2008;283:25774–25785. [PubMed: 18559338]
94. Adachi T, Inoue M, Hara H, Suzuki S. Effects of PPARgamma ligands and C/EBPbeta enhancer on expression of extracellular-superoxide dismutase. *Redox Rep* 2004;9:207–212. [PubMed: 15479564]
95. Yoo HY, Chang MS, Rho HM. Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid. *Gene* 1999;234:87–91. [PubMed: 10393242]
96. Chang MS, Yoo HY, Rho HM. Positive and negative regulatory elements in the upstream region of the rat Cu/Zn-superoxide dismutase gene. *Biochem J* 1999;339(Pt 2):335–341. [PubMed: 10191264]
97. Cho G, Kang S, Seo SJ, Kim Y, Jung G. The transcriptional repression of the human Cu/Zn superoxide dismutase(sod1) gene by the anticancer drug, mitomycin C(MMC). *Biochem Mol Biol Int* 1997;42:949–956. [PubMed: 9285062]
98. Park EY, Rho HM. The transcriptional activation of the human copper/zinc superoxide dismutase gene by 2,3,7,8-tetrachlorodibenzo-p-dioxin through two different regulator sites, the antioxidant responsive element and xenobiotic responsive element. *Mol Cell Biochem* 2002;240:47–55. [PubMed: 12487371]

99. Kops GJ, D T, Polderman PE, Saarloos I, Wirtz KW, Coffey PJ, Huang TT, Bos JL, Medema RH, Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* 2002;419:316–321. [PubMed: 12239572]
100. Li M, Chiu JF, Mossman BT, Fukagawa NK. Down-regulation of manganese-superoxide dismutase through phosphorylation of FOXO3a by Akt in explanted vascular smooth muscle cells from old rats. *J Biol Chem* 2006;281:40429–40439. [PubMed: 17079231]
101. Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen YE, Schneider MD, Mangelsdorf DJ, Evans RM, Yang Q. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. *Cardiovasc Res* 2007;76:269–279. [PubMed: 17678635]
102. Jeney V, Itoh S, Wendt M, Gradek Q, Ushio-Fukai M, Harrison DG, Fukai T. Role of antioxidant-1 in extracellular superoxide dismutase function and expression. *Circ Res* 2005;96:723–729. [PubMed: 15761197]
103. Qin Z, Itoh S, Jeney V, Ushio-Fukai M, Fukai T. Essential role for the Menkes ATPase in activation of extracellular superoxide dismutase: implication for vascular oxidative stress. *FASEB J* 2006;20:334–336. [PubMed: 16371425]
104. Qin Z, Gongora MC, Ozumi K, Itoh S, Akram K, Ushio-Fukai M, Harrison DG, Fukai T. Role of Menkes ATPase in angiotensin II-induced hypertension: a key modulator for extracellular superoxide dismutase function. *Hypertension* 2008;52:945–951. [PubMed: 18768397]
105. Zelko IN, Folz RJ. Myeloid zinc finger (MZF)-like, Kruppel-like and Ets families of transcription factors determine the cell-specific expression of mouse extracellular superoxide dismutase. *Biochem J* 2003;369:375–386. [PubMed: 12374566]
106. Huang Y, He T, Domann FE. Decreased expression of manganese superoxide dismutase in transformed cells is associated with increased cytosine methylation of the SOD2 gene. *DNA Cell Biol* 1999;18:643–652. [PubMed: 10463060]
107. Hitchler MJ, Wikainapakul K, Yu L, Powers K, Attatippaholkun W, Domann FE. Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells. *Epigenetics* 2006;1:163–171. [PubMed: 17965603]
108. Hitchler MJ, Oberley LW, Domann FE. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells. *Free Radic Biol Med* 2008;45:1573–1580. [PubMed: 18845242]
109. Hurt EM, Thomas SB, Peng B, Farrar WL. Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines. *Br J Cancer* 2007;97:1116–1123. [PubMed: 17895890]
110. Hodge DR, Peng B, Pompeia C, Thomas S, Cho E, Clausen PA, Marquez VE, Farrar WL. Epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. *Cancer Biol Ther* 2005;4:585–592. [PubMed: 15908783]
111. Maehara K, Uekawa N, Isobe K. Effects of histone acetylation on transcriptional regulation of manganese superoxide dismutase gene. *Biochem Biophys Res Commun* 2002;295:187–192. [PubMed: 12083788]
112. Oates N, Pamphlett R. An epigenetic analysis of SOD1 and VEGF in ALS. *Amyotroph Lateral Scler* 2007;8:83–86. [PubMed: 17453634]
113. Hirsch S, Ronco AM, Guerrero-Bosagna C, de la Maza MP, Leiva L, Barrera G, Llanos M, Alliende MA, Silva F, Bunout D. Methylation status in healthy subjects with normal and high serum folate concentration. *Nutrition* 2008;24:1103–1109. [PubMed: 18653314]
114. Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomaki S, Airenne K, Janne J, Yla-Herttuala S. Local hypomethylation in atherosclerosis found in rabbit *ec-sod* gene. *Arterioscler Thromb Vasc Biol* 1999;19:2171–2178. [PubMed: 10479660]
115. Davis CA, Monnier JM, Nick HS. A coding region determinant of instability regulates levels of manganese superoxide dismutase mRNA. *J Biol Chem* 2001;276:37317–37326. [PubMed: 11489890]
116. Stuart JJ, Egry LA, Wong GH, Kaspar RL. The 3' UTR of human MnSOD mRNA hybridizes to a small cytoplasmic RNA and inhibits gene expression. *Biochem Biophys Res Commun* 2000;274:641–648. [PubMed: 10924331]

117. Smalheiser NR, Torvik VI. Alu elements within human mRNAs are probable microRNA targets. *Trends in Genetics* 2006;22:532–536. [PubMed: 16914224]
118. Rabani M, Kertesz M, Segal E. Computational prediction of RNA structural motifs involved in posttranscriptional regulatory processes. *Proc Natl Acad Sci U S A* 2008;105:14885–14890. [PubMed: 18815376]
119. Fazzone H, Wangner A, Clerch LB. Rat lung contains a developmentally regulated manganese superoxide dismutase mRNA-binding protein. *J Clin Invest* 1993;92:1278–1281. [PubMed: 8376586]
120. Chung DJ, Clerch LB. RNA in polysomes is an inhibitor of manganese superoxide dismutase RNA-binding protein activity. *Am J Physiol* 1997;272:L714–719. [PubMed: 9142946]
121. Clerch LB. Post-transcriptional regulation of lung antioxidant enzyme gene expression. *Ann N Y Acad Sci* 2000;899:103–111. [PubMed: 10863532]
122. Chung DJ, Wright AE, Clerch LB. The 3' untranslated region of manganese superoxide dismutase RNA contains a translational enhancer element. *Biochemistry* 1998;37:16298–16306. [PubMed: 9819222]
123. Knirsch L, Clerch LB. A region in the 3' UTR of MnSOD RNA enhances translation of a heterologous RNA. *Biochem Biophys Res Commun* 2000;272:164–168. [PubMed: 10872821]
124. Knirsch L, Clerch LB. Tyrosine phosphorylation regulates manganese superoxide dismutase (MnSOD) RNA-binding protein activity and MnSOD protein expression. *Biochemistry* 2001;40:7890–7895. [PubMed: 11425317]
125. Kilk A, Laan M, Torp A. Human CuZn superoxide dismutase enzymatic activity in cells is regulated by the length of the mRNA. *FEBS Lett* 1995;362:323–327. [PubMed: 7729522]
126. Shaw PJ, Tomkins J, Slade JY, Usher P, Curtis A, Bushby K, Ince PG. CNS tissue Cu/Zn superoxide dismutase (SOD1) mutations in motor neurone disease (MND). *Neuroreport* 1997;8:3923–3927. [PubMed: 9462467]
127. Mirossay A, Jun S, Dory L. Cloning and characterization of two alleles of the murine extracellular superoxide dismutase gene. *Biochem Biophys Res Commun* 2007;352:739–743. [PubMed: 17150184]
128. Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. *J Biol Chem* 2001;276:38388–38393. [PubMed: 11507097]
129. Orrell R, de Belleruche J, Marklund S, Bowe F, Hallewell R. A novel SOD mutant and ALS. *Nature* 1995;374:504–505. [PubMed: 7700376]
130. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 1993;364:362. [PubMed: 8332197]
131. Turner BJ, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. *Prog Neurobiol* 2008;85:94–134. [PubMed: 18282652]
132. Wroe R, Wai-Ling Butler A, Andersen PM, Powell JF, Al-Chalabi A. ALSOD: the Amyotrophic Lateral Sclerosis Online Database. *Amyotroph Lateral Scler* 2008;9:249–250. [PubMed: 18608099]
133. Niemann S, Broom WJ, Brown RH Jr. Analysis of a genetic defect in the TATA box of the SOD1 gene in a patient with familial amyotrophic lateral sclerosis. *Muscle Nerve* 2007;36:704–707. [PubMed: 17636481]
134. Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. *Annu Rev Neurosci* 2004;27:723–749. [PubMed: 15217349]
135. Furukawa Y, Kaneko K, Yamanaka K, O'Halloran TV, Nukina N. Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. *J Biol Chem* 2008;283:24167–24176. [PubMed: 18552350]
136. Valentine JS, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. *Annu Rev Biochem* 2005;74:563–593. [PubMed: 15952898]
137. Borgstahl GE, Parge HE, Hickey MJ, Beyer WF Jr, Hallewell RA, Tainer JA. The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. *Cell* 1992;71:107–118. [PubMed: 1394426]
138. Beckman JS, Esetvez AG, Barbeito L, Crow JP. CCS knockout mice establish an alternative source of copper for SOD in ALS. *Free Radic Biol Med* 2002;33:1433–1435. [PubMed: 12419475]

139. Furukawa Y, O'Halloran TV. Posttranslational modifications in Cu,Zn-superoxide dismutase and mutations associated with amyotrophic lateral sclerosis. *Antioxid Redox Signal* 2006;8:847–867. [PubMed: 16771675]
140. Carroll MC, Outten CE, Proescher JB, Rosenfeld L, Watson WH, Whitson LJ, Hart PJ, Jensen LT, Cizewski Culotta V. The effects of glutaredoxin and copper activation pathways on the disulfide and stability of Cu,Zn superoxide dismutase. *J Biol Chem* 2006;281:28648–28656. [PubMed: 16880213]
141. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. *J Neurochem* 1997;69:1936–1944. [PubMed: 9349538]
142. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, Barbeito L, Beckman JS. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. *Science* 1999;286:2498–2500. [PubMed: 10617463]
143. Roberts BR, Tainer JA, Getzoff ED, Malencik DA, Anderson SR, Bomben VC, Meyers KR, Karplus PA, Beckman JS. Structural characterization of zinc-deficient human superoxide dismutase and implications for ALS. *J Mol Biol* 2007;373:877–890. [PubMed: 17888947]
144. Groeneveld GJ, de Leeuw van Weenen J, van Muiswinkel FL, Veldman H, Veldink JH, Wokke JH, Bar PR, van den Berg LH. Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis. *Neurosci Lett* 2003;352:175–178. [PubMed: 14625013]
145. Ermilova IP, Ermilov VB, Levy M, Ho E, Pereira C, Beckman JS. Protection by dietary zinc in ALS mutant G93A SOD transgenic mice. *Neurosci Lett* 2005;379:42–46. [PubMed: 15814196]
146. McCord JM, Fridovich I. Superoxide dismutase: the first twenty years (1968-1988). *Free Radic Biol Med* 1988;5:363–369. [PubMed: 2855736]
147. Oberley LW, Buettner GR. Role of superoxide dismutase in cancer: a review. *Cancer Res* 1979;39:1141–1149. [PubMed: 217531]
148. Carlioz A, Touati D. Isolation of superoxide dismutase mutants in *Escherichia coli*: is superoxide dismutase necessary for aerobic life? *EMBO J* 1986;5:623–630. [PubMed: 3011417]
149. Li Y, Huang TT, Carlson EJ, Melov S, Ursell PC, Olson JL, Noble LJ, Yoshimura MP, Berger C, Chan PH, Wallace DC, Epstein CJ. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. *Nat Genet* 1995;11:376–381. [PubMed: 7493016]
150. Lebovitz RM, Zhang H, Vogel H, Cartwright J Jr, Dionne L, Lu N, Huang S, Matzuk MM. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. *Proc Natl Acad Sci U S A* 1996;93:9782–9787. [PubMed: 8790408]
151. Kinnula VL, Crapo JD. Superoxide dismutases in malignant cells and human tumors. *Free Radic Biol Med* 2004;36:718–744. [PubMed: 14990352]
152. Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. *Biomed Pharmacother* 2005;59:143–148. [PubMed: 15862707]
153. Devi GS, Prasad MH, Saraswathi I, Raghu D, Rao DN, Reddy PP. Free radicals antioxidant enzymes and lipid peroxidation in different types of leukemias. *Clin Chim Acta* 2000;293:53–62. [PubMed: 10699422]
154. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. *J Biol Chem* 2005;280:39485–39492. [PubMed: 16179351]
155. Xu Y, Krishnan A, Wan XS, Majima H, Yeh CC, Ludewig G, Kasarskis EJ, St Clair DK. Mutations in the promoter reveal a cause for the reduced expression of the human manganese superoxide dismutase gene in cancer cells. *Oncogene* 1999;18:93–102. [PubMed: 9926924]
156. Rosenblum JS, Gilula NB, Lerner RA. On signal sequence polymorphisms and diseases of distribution. *Proc Natl Acad Sci U S A* 1996;93:4471–4473. [PubMed: 8633092]
157. Borgstahl GE, Parge HE, Hickey MJ, Johnson MJ, Boissinot M, Hallewell RA, Lepock JR, Cabelli DE, Tainer JA. Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface. *Biochemistry* 1996;35:4287–4297. [PubMed: 8605177]

158. Hernandez-Saavedra D, McCord JM. Paradoxical effects of thiol reagents on Jurkat cells and a new thiol-sensitive mutant form of human mitochondrial superoxide dismutase. *Cancer Res* 2003;63:159–163. [PubMed: 12517793]
159. Nakanishi S, Y K, Ohishi W, Nakashima R, Yoneda M, Nojima H, Watanabe H, Kohno N. Manganese superoxide dismutase Ala16Val polymorphism is associated with the development of type 2 diabetes in Japanese-Americans. *Diabetes research and clinical practice*. 2008
160. Hirooka Y. Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. *Auton Neurosci* 2008;142:20–24. [PubMed: 18650132]
161. Arsova-Sarafinovska Z, M N, Petrovski D, Banev S, Dzikova S, Georgiev V, Sikole A, Sayal A, Aydin A, Suturkova L, Dimovski AJ. Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer. *Cell biochemistry and function*. 2008
162. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW Jr, Giovannucci E. Manganese Superoxide Dismutase (MnSOD) Gene Polymorphism, Interactions with Carotenoid Levels, and Prostate Cancer Risk. *Carcinogenesis*. 2008
163. St Clair D, Kasarskis E. Genetic polymorphism of the human manganese superoxide dismutase: what difference does it make? *Pharmacogenetics* 2003;13:129–130. [PubMed: 12618590]
164. Sutton A, Khoury H, Prip-Buus C, Capanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. *Pharmacogenetics* 2003;13:145–157. [PubMed: 12618592]
165. Bag A, Bag N. Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: a review. *Cancer Epidemiol Biomarkers Prev* 2008;17:3298–3305. [PubMed: 19064542]
166. Wheatley-Price P, Asomaning K, Reid A, Zhai R, Su L, Zhou W, Zhu A, Ryan DP, Christiani DC, Liu G. Myeloperoxidase and superoxide dismutase polymorphisms are associated with an increased risk of developing pancreatic adenocarcinoma. *Cancer* 2008;112:1037–1042. [PubMed: 18205184]
167. Liu G, Zhou W, Park S, Wang LI, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms. *Cancer* 2004;101:2802–2808. [PubMed: 15534883]
168. Holla LI, Kankova K, Vasku A. Functional polymorphism in the manganese superoxide dismutase (MnSOD) gene in patients with asthma. *Clin Biochem* 2006;39:299–302. [PubMed: 16423340]
169. Singh M, Khan AJ, Shah PP, Shukla R, Khanna VK, Parmar D. Polymorphism in environment responsive genes and association with Parkinson disease. *Mol Cell Biochem* 2008;312:131–138. [PubMed: 18327668]
170. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. *Cancer Res* 2005;65:2498–2504. [PubMed: 15781667]
171. Ho JC, Mak JC, Ho SP, Ip MS, Tsang KW, Lam WK, Chan-Yeung M. Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong. *J Thorac Oncol* 2006;1:648–653. [PubMed: 17409931]
172. Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J, Albanes D. Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). *Cancer Causes Control* 2003;14:513–518. [PubMed: 12948282]
173. Olson SH, Carlson MD, Ostrer H, Harlap S, Stone A, Winters M, Ambrosone CB. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. *Gynecol Oncol* 2004;93:615–620. [PubMed: 15196853]
174. Zhang HJ, Yan T, Oberley TD, Oberley LW. Comparison of effects of two polymorphic variants of manganese superoxide dismutase on human breast MCF-7 cancer cell phenotype. *Cancer Res* 1999;59:6276–6283. [PubMed: 10626823]
175. Marklund SL. Human copper-containing superoxide dismutase of high molecular weight. *Proc Natl Acad Sci U S A* 1982;79:7634–7638. [PubMed: 6961438]
176. Marklund SL, Holme E, Hellner L. Superoxide dismutase in extracellular fluids. *Clin Chim Acta* 1982;126:41–51. [PubMed: 7172448]

177. Marklund SL. Extracellular superoxide dismutase. *Methods Enzymol* 2002;349:74–80. [PubMed: 11912931]
178. Karlsson K, Lindahl U, Marklund SL. Binding of human extracellular superoxide dismutase C to sulphated glycosaminoglycans. *Biochem J* 1988;256:29–33. [PubMed: 3223905]
179. Tibell LA, Sethson I, Buevich AV. Characterization of the heparin-binding domain of human extracellular superoxide dismutase. *Biochim Biophys Acta* 1997;1340:21–32. [PubMed: 9217011]
180. Gao F, Koenitzer JR, Tobolewski JM, Jiang D, Liang J, Noble PW, Oury TD. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. *J Biol Chem* 2008;283:6058–6066. [PubMed: 18165226]
181. Sandstrom J, Nilsson P, Karlsson K, Marklund SL. 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. *J Biol Chem* 1994;269:19163–19166. [PubMed: 8034674]
182. Adachi T, Yamada H, Yamada Y, Morihara N, Yamazaki N, Murakami T, Futenma A, Kato K, Hirano K. Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface. *Biochem J* 1996;313(Pt 1):235–239. [PubMed: 8546689]
183. Qin Z, Reszka KJ, Fukai T, Weintraub NL. Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD. *Transl Res* 2008;151:68–78. [PubMed: 18201674]
184. Campo S, Sardo AM, Campo GM, D'Ascola A, Avenoso A, Castaldo M, Saitta C, Lania A, Saitta A, Calatroni A. Extracellular superoxide dismutase (EC-SOD) gene mutations screening in a sample of Mediterranean population. *Mutat Res* 2005;578:143–148. [PubMed: 15899505]
185. Tamai M, Furuta H, Kawashima H, Doi A, Hamanishi T, Shimomura H, Sakagashira S, Nishi M, Sasaki H, Sanke T, Nanjo K. Extracellular superoxide dismutase gene polymorphism is associated with insulin resistance and the susceptibility to type 2 diabetes. *Diabetes Res Clin Pract* 2006;71:140–145. [PubMed: 15990193]
186. Petersen SV, Oury TD, Valnickova Z, Thogersen IB, Hojrup P, Crapo JD, Enghild JJ. The dual nature of human extracellular superoxide dismutase: one sequence and two structures. *Proc Natl Acad Sci U S A* 2003;100:13875–13880. [PubMed: 14615576]
187. Petersen SV, Kristensen T, Petersen JS, Ramsgaard L, Oury TD, Crapo JD, Nielsen NC, Enghild JJ. The folding of human active and inactive extracellular superoxide dismutases is an intracellular event. *J Biol Chem* 2008;283:15031–15036. [PubMed: 18385137]
188. Olsen DA, Petersen SV, Oury TD, Valnickova Z, Thogersen IB, Kristensen T, Bowler RP, Crapo JD, Enghild JJ. The intracellular proteolytic processing of extracellular superoxide dismutase (EC-SOD) is a two-step event. *J Biol Chem* 2004;279:22152–22157. [PubMed: 15044467]
189. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, Harrison DG. Role of extracellular superoxide dismutase in hypertension. *Hypertension* 2006;48:473–481. [PubMed: 16864745]
190. Nguyen AD, Itoh S, Jeney V, Yanagisawa H, Fujimoto M, Ushio-Fukai M, Fukai T. Fibulin-5 is a novel binding protein for extracellular superoxide dismutase. *Circ Res* 2004;95:1067–1074. [PubMed: 15528465]


Genetic structure and regulatory elements of *sod1* gene

Figure 1. Organization of the *sod1* gene

The EntrezGeneID of each gene from the NCBI database is indicated on the left. Solid boxes and the associated numbers indicate exons and the size of each exon in base pairs. Lines and numbers between each exon indicate introns and the corresponding size. The regulatory elements in the 5' flanking region for the human *sod1* are expanded and shown in the lower part. The transcription start site is indicated by an arrow and designated +1. Binding sites for transcription factors known to play a regulatory role are placed according to the location of the corresponding regulatory elements identified in published literature and are indicated by numbers on the bottom part of the figure.


Genetic structure and regulatory elements of *sod2* gene

Figure 2. Organization of the *sod2* gene

The EntrzGeneID of each gene from the database, the size of exons and introns, and the transcriptional start site are organized as described for *sod1*. The regulatory elements identified in the 5' flanking region and the second intron of the human *sod2* are expanded and shown in the lower part. Corresponding numbers with positive and negative numbers indicate their location relative to the start site, which is designated +1.


Genetic structure and regulatory elements of *sod3* gene

Figure 3. Organization of the *sod3* gene

The EnzGeneID of each gene from the database, the size of exons and introns, and the transcriptional start site are organized as described for *sod1*. The first exon of the human *sod3* has been added according to the information extracted from the original publication. This exon was not present in the data base indicated by EnzGeneID #6649.

Table 1
Summarized characteristics of three superoxide dismutases in eukaryotic cells

Isoform	Location	MW/kDa	Assembly of subunits	Metal ion	Ion-delivery related protein
Cu/ZnSOD	cytoplasm, nucleus, mitochondrial membrane	88	homodimer	Cu ²⁺ (catalytic active)	CCS (copper chaperone for SOD1) [11-13] GSH (glutathione, secondary chaperone) [14] metallothioneins; ZnT (zinc transporter) [15]
MnSOD	mitochondria matrix	32	homotetramer	Zn ²⁺ (maintain enzyme stability) Mn ²⁺ (catalytic active)	Smf2p (manganese trafficking factor for mitochondrial SOD2) [16] MTM1 (manganese trafficking factor for mitochondrial SOD2)* [17,18] Atox1 (antioxidant-1, copper chaperone) [19]
ECSOD	plasma membrane, extracellular fluids	135	homotetrameric glycoprotein	Cu ²⁺ (catalytic active) Zn ²⁺ (maintain enzyme stability)	MNK (Menkes ATPase) [20] N/A

* the metal transporter which is found in *Saccharomyces cerevisiae*.

Table 2Identified variants of the human *sod2* gene

Mutation/SNP	Position	Physiological function	Reference
non-coding region			
C to T	-102 (promoter)	down-regulate <i>sod2</i> expression by interrupting the single-loop structure	[75,155]
insertion A	-93 (promoter)	down-regulate <i>sod2</i> expression by interrupting the single-loop structure	[75,155]
C to G	-38 (promoter)	AP-2 dependent dysregulation of <i>sod2</i> expression	[85,155]
coding region			
GCT (Ala) to GTT (Val)	16 [*] (presequence)	MnSOD mitochondrial targeting sequence	[156]
ATA (Ile) to ACA (Thr)	58 (exon 3)	reduce MnSOD activity by destabilizing the tetrameric interface	[157]
CTT (Leu) to TTT (Phe)	60 (exon 3)	deficiency in MnSOD activity	[158]

* Based on codon position